William C. Hahn, MD, PhD

William C. Hahn, MD, PhD

Medical Oncology

Contact Information

Office Phone Number





877-332-4294 (new)


William C. Hahn, MD, PhD

Dr. William C. Hahn is the William Rosenberg Professor of Medicine in the Department of Medical Oncology at Dana-Farber Cancer Institute and Harvard Medical School and an Institute Member of the Broad Institute of MIT and Harvard. He serves as an Executive Vice President and the Chief Operating Officer at the Dana-Farber Cancer Institute.

Dr. Hahn has made numerous discoveries that have informed our current molecular understanding of cancer. His laboratory has pioneered the use of integrated functional genomic approaches to identify and validate cancer targets. The tools, models and approaches that his laboratory has developed are widely used worldwide to discover and validate molecularly targeted cancer therapies.

Dr. Hahn has served as the President of the American Society for Clinical Investigation and has been elected to the Association of American Physicians and the National Academy of Medicine. Dr. Hahn has been the recipient of many honors and awards including the Wilson S. Stone Award from M.D. Anderson Cancer Center for outstanding research in cancer (2000), a Howard Temin Award from the National Cancer Institute (2001), the Ho-Am Prize in Medicine (2010), the Richard and Hinda Rosenthal Award from AACR (2015) and the Claire and Richard Morse Award (2019). He has been elected to the American Society of Clinical Investigation, American Association of Physicians, the National Academy of Inventors and the National Academy of Medicine.



Executive Vice President and Chief Operating Officer
William Rosenberg Professor of Medicine, Harvard Medical School
Institute Member, Broad Institute of Harvard and MIT


Clinical Interests

Prostate cancer, Translational research

Board Certification

  • Internal Medicine, 1997
  • Medical Oncology, 2000


  • Dana-Farber/Partners CancerCare, Medical Oncology


  • Massachusetts General Hospital, Internal Medicine

Medical School

  • Harvard Medical School

Recent Awards

  • Elected to the American Society of Clinical Investigation 2005
  • Wilson S. Stone Memorial Award, MD Anderson Cancer Center 2000
  • Gill-Simonian Prize for Mentoring


  • Ho-Am Laureate in Medicine


  • Elected to Association of American Physicians



    Functional genomics and human cell transformation, Precision cancer medicine

    My work as a physician-scientist involves both the care of cancer patients and biomedical research directed toward a greater understanding of the mechanisms involved in malignant transformation. My laboratory focuses on understanding the cooperative interactions that conspire to transform human cells. To address this question, we have developed new experimental models of human cancer of defined genetic composition, created methods to perform systematic interrogation of gene function in mammalian cells and tissues and help optimize new approaches to integrate genome scale data. Using these approaches, we have identified and credential new oncogenes and tumor suppressor genes and have performed preclinical studies that will form the foundation necessary for translational studies in patients.

    Specifically, we have developed genetic methods that permit the construction of genetically defined, experimental models of the major human epithelial cancers from primary human cells through the manipulation of oncogenes, tumor suppressor genes and telomerase. These model systems have permitted us to study the molecular interactions that lead to cancer. In addition, we have performed proof-of-principle experiments that such experimental models will prove useful in the discovery and validation of molecularly targeted therapies. Indeed, these experimental models have allowed us to investigate the mechanisms by which EGFR and other oncogenes and tumor suppressors contribute to cancer initiation. In particular, we have elucidated the role of the PP2A family of serine-threonine phosphatases as tumor suppressor genes.

    As a Senior Associate Member of the Broad Institute, I lead efforts to apply functional genomic approaches to cancer. Specifically, I serve as one of the co-principal investigators for the RNAi Consortium (TRC), which has created a genome scale RNA interference library, and have established RNAi screening facilities at both the Broad Institute and the Dana-Farber Cancer Institute (DFCI). In my own laboratory, we are engaged in using these RNAi libraries to apply a comprehensive program to identify cancer vulnerabilities. Using these approaches, we have already discovered several new oncogenes including IKBKE, CDK8, CRKL, CDK6, and PAK1. I also co-direct the Center for Cancer Genome Discovery, which is committed to the development and implementation of technologies that permit the interrogation of cancer-associated mutations at genome scale and to implement these technologies prospectively in newly diagnosed patients.

    Research Website



      • Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal. Genome Biol. 2023 08 23; 24(1):192. View in: Pubmed

      • Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. Nat Cancer. 2023 05; 4(5):754-773. View in: Pubmed

      • USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell Rep Med. 2023 04 18; 4(4):101007. View in: Pubmed

      • Mapping the landscape of genetic dependencies in chordoma. Nat Commun. 2023 04 06; 14(1):1933. View in: Pubmed

      • Aberrant cell state plasticity mediated by developmental reprogramming precedes colorectal cancer initiation. Sci Adv. 2023 03 29; 9(13):eadf0927. View in: Pubmed

      • A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas. Cancer Discov. 2023 03 01; 13(3):766-795. View in: Pubmed

      • Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. Cancer Res. 2023 02 15; 83(4):613-625. View in: Pubmed

      • Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Cancer Res. 2023 02 03; 83(3):441-455. View in: Pubmed

      • Discovery of antibodies and cognate surface targets for ovarian cancer by surface profiling. Proc Natl Acad Sci U S A. 2023 01 03; 120(1):e2206751120. View in: Pubmed

      • Author Correction: Massively parallel phenotyping of coding variants in cancer with Perturb-seq. Nat Biotechnol. 2022 Nov; 40(11):1691. View in: Pubmed

      • VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system. JCI Insight. 2022 10 10; 7(19). View in: Pubmed

      • Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex. Nature. 2022 09; 609(7926):408-415. View in: Pubmed

      • Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. Nat Cancer. 2022 06; 3(6):681-695. View in: Pubmed

      • Serological testing for SARS-CoV-2 antibodies of employees shows low transmission working in a cancer center. PLoS One. 2022; 17(4):e0266791. View in: Pubmed

      • Author Correction: Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun. 2022 Apr 01; 13(1):1894. View in: Pubmed

      • PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. J Immunother Cancer. 2022 03; 10(3). View in: Pubmed

      • A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer. Cell Rep. 2022 02 22; 38(8):110417. View in: Pubmed

      • Sparse dictionary learning recovers pleiotropy from human cell fitness screens. Cell Syst. 2022 04 20; 13(4):286-303.e10. View in: Pubmed

      • Massively parallel phenotyping of coding variants in cancer with Perturb-seq. Nat Biotechnol. 2022 06; 40(6):896-905. View in: Pubmed

      • YAP1 and PRDM14 converge to promote cell survival and tumorigenesis. Dev Cell. 2022 01 24; 57(2):212-227.e8. View in: Pubmed

      • Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol. 2021 12 20; 22(1):343. View in: Pubmed

      • Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021 12 09; 184(25):6119-6137.e26. View in: Pubmed

      • Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021 12 16; 385(25):2348-2360. View in: Pubmed

      • Biologically informed deep neural network for prostate cancer discovery. Nature. 2021 10; 598(7880):348-352. View in: Pubmed

      • SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization. Cell Rep. 2021 07 27; 36(4):109443. View in: Pubmed

      • Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. Genome Med. 2021 07 14; 13(1):114. View in: Pubmed

      • Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2021 Jul 13; 36(2):109367. View in: Pubmed

      • FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 10; 11(10):2488-2505. View in: Pubmed

      • Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun. 2021 03 30; 12(1):1979. View in: Pubmed

      • A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective. Mol Cell Biol. 2021 03 24; 41(4). View in: Pubmed

      • A first-generation pediatric cancer dependency map. Nat Genet. 2021 04; 53(4):529-538. View in: Pubmed

      • An expanded universe of cancer targets. Cell. 2021 03 04; 184(5):1142-1155. View in: Pubmed

      • Predicting cell health phenotypes using image-based morphology profiling. Mol Biol Cell. 2021 04 19; 32(9):995-1005. View in: Pubmed

      • Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Rep. 2021 01 05; 34(1):108532. View in: Pubmed

      • Global computational alignment of tumor and cell line transcriptional profiles. Nat Commun. 2021 01 04; 12(1):22. View in: Pubmed

      • Cancer research needs a better map. Nature. 2021 01; 589(7843):514-516. View in: Pubmed

      • Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2020 12 15; 33(11):108493. View in: Pubmed

      • Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine. Clin Cancer Res. 2020 09 15; 26(18):4995-5006. View in: Pubmed

      • Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020 06; 16(6):635-643. View in: Pubmed

      • Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci Rep. 2020 03 24; 10(1):5324. View in: Pubmed

      • ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Res. 2020 06 01; 80(11):2094-2100. View in: Pubmed

      • STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells. Elife. 2020 Jan 08; 9. View in: Pubmed

      • Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets. Nat Commun. 2019 12 20; 10(1):5817. View in: Pubmed

      • CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Rep. 2019 11 19; 29(8):2355-2370.e6. View in: Pubmed

      • Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Rep. 2019 10 01; 29(1):118-134.e8. View in: Pubmed

      • Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. Cell Rep. 2019 08 27; 28(9):2331-2344.e8. View in: Pubmed

      • A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019 08 09; 365(6453):599-604. View in: Pubmed

      • A CRISPR Way to Identify Cancer Targets. N Engl J Med. 2019 Jun 20; 380(25):2475-2477. View in: Pubmed

      • Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019 06 03; 10(1):2400. View in: Pubmed

      • TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 08; 9(8):1064-1079. View in: Pubmed

      • Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019 05; 569(7757):503-508. View in: Pubmed

      • The landscape of cancer cell line metabolism. Nat Med. 2019 05; 25(5):850-860. View in: Pubmed

      • Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers. Cancer Res. 2019 05 15; 79(10):2564-2579. View in: Pubmed

      • Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8. View in: Pubmed

      • Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. Cell Metab. 2019 05 07; 29(5):1166-1181.e6. View in: Pubmed

      • MCL1 and DEDD Promote Urothelial Carcinoma Progression. Mol Cancer Res. 2019 06; 17(6):1294-1304. View in: Pubmed

      • MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Cancer Res. 2019 05 01; 79(9):2404-2414. View in: Pubmed

      • Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nat Med. 2019 02; 25(2):292-300. View in: Pubmed

      • Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun. 2018 12 21; 9(1):5450. View in: Pubmed

      • Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018 12 13; 175(7):1972-1988.e16. View in: Pubmed

      • Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018 11 02; 3(21). View in: Pubmed

      • Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat Commun. 2018 11 02; 9(1):4610. View in: Pubmed

      • Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018 10; 50(10):1381-1387. View in: Pubmed

      • Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat Genet. 2018 09; 50(9):1240-1246. View in: Pubmed

      • iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther. 2018 11; 17(11):2377-2388. View in: Pubmed

      • Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. Mol Cell. 2018 08 16; 71(4):554-566.e7. View in: Pubmed

      • Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers. Cold Spring Harb Perspect Med. 2018 08 01; 8(8). View in: Pubmed

      • Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2019 02; 37(1):159-165. View in: Pubmed

      • An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. Elife. 2018 07 30; 7. View in: Pubmed

      • Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019 01; 21(1):213-223. View in: Pubmed

      • Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet. 2018 07; 50(7):937-943. View in: Pubmed

      • Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111. View in: Pubmed

      • A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell. 2018 07 12; 174(2):422-432.e13. View in: Pubmed

      • Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018 05 22; 9(1):2024. View in: Pubmed

      • Interrogation of Mammalian Protein Complex Structure, Function, and Membership Using Genome-Scale Fitness Screens. Cell Syst. 2018 05 23; 6(5):555-568.e7. View in: Pubmed

      • Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420. View in: Pubmed

      • Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2017; 1. View in: Pubmed

      • NetSig: network-based discovery from cancer genomes. Nat Methods. 2018 01; 15(1):61-66. View in: Pubmed

      • CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest. 2018 01 02; 128(1):446-462. View in: Pubmed

      • Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017 12 15; 358(6369):1443-1448. View in: Pubmed

      • Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 10 31; 6. View in: Pubmed

      • Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017 Dec; 49(12):1779-1784. View in: Pubmed

      • A Community Challenge for Inferring Genetic Predictors of Gene Essentialities through Analysis of a Functional Screen of Cancer Cell Lines. Cell Syst. 2017 11 22; 5(5):485-497.e3. View in: Pubmed

      • Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. Cancer Discov. 2018 01; 8(1):108-125. View in: Pubmed

      • Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. Cell Syst. 2017 08 23; 5(2):105-118.e9. View in: Pubmed

      • Defining a Cancer Dependency Map. Cell. 2017 Jul 27; 170(3):564-576.e16. View in: Pubmed

      • Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017 07 27; 547(7664):453-457. View in: Pubmed

      • PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer. Cancer Res. 2017 09 01; 77(17):4613-4625. View in: Pubmed

      • Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun. 2017 06 13; 8:15918. View in: Pubmed

      • A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 2017 06 01; 19(6):774-785. View in: Pubmed

      • Synergistic interactions with PI3K inhibition that induce apoptosis. Elife. 2017 05 31; 6. View in: Pubmed

      • Complementary information derived from CRISPR Cas9 mediated gene deletion and suppression. Nat Commun. 2017 05 23; 8:15403. View in: Pubmed

      • Going beyond genetics to discover cancer targets. Genome Biol. 2017 05 22; 18(1):95. View in: Pubmed

      • PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun. 2017 04 27; 8:15110. View in: Pubmed

      • PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc Natl Acad Sci U S A. 2017 04 25; 114(17):E3434-E3443. View in: Pubmed

      • Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife. 2017 02 08; 6. View in: Pubmed

      • ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. Cell Rep. 2017 02 07; 18(6):1543-1557. View in: Pubmed

      • KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 02 01; 6. View in: Pubmed

      • Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6. Cancer Res. 2017 02 01; 77(3):753-765. View in: Pubmed

      • Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062. View in: Pubmed

      • Functional Genomic Characterization of Cancer Genomes. Cold Spring Harb Symp Quant Biol. 2016; 81:237-246. View in: Pubmed

      • The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood. 2017 01 26; 129(4):497-508. View in: Pubmed

      • Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in ß-Catenin-Active Cancers. Cell Syst. 2016 09 28; 3(3):302-316.e4. View in: Pubmed

      • Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 01; 19(1):22-30. View in: Pubmed

      • Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer. 2016 06 28; 115(1):12-9. View in: Pubmed

      • Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016 06 22; 7:11987. View in: Pubmed

      • Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016 08; 6(8):914-29. View in: Pubmed

      • Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer Discov. 2016 07; 6(7):714-26. View in: Pubmed

      • Characterizing genomic alterations in cancer by complementary functional associations. Nat Biotechnol. 2016 05; 34(5):539-46. View in: Pubmed

      • MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016 Mar 11; 351(6278):1214-8. View in: Pubmed

      • TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 2015 Dec 14; 4:e176. View in: Pubmed

      • Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Mol Cancer Res. 2016 Feb; 14(2):207-15. View in: Pubmed

      • SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med. 2015 Dec; 21(12):1491-6. View in: Pubmed

      • Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. Elife. 2015 Oct 24; 4. View in: Pubmed

      • The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015 Nov; 47(11):1346-51. View in: Pubmed

      • AACR Cancer Progress Report 2015. Clin Cancer Res. 2015 Oct 01; 21(19 Suppl):S1-128. View in: Pubmed

      • Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177. View in: Pubmed

      • Oncogenic Signaling Adaptor Proteins. J Genet Genomics. 2015 Oct 20; 42(10):521-529. View in: Pubmed

      • Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7. View in: Pubmed

      • Correction for Hwang et al., Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. J Virol. 2015 Jul; 89(13):6971. View in: Pubmed

      • DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015 Apr; 21(4):335-43. View in: Pubmed

      • A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 2015 Mar 09; 27(3):397-408. View in: Pubmed

      • Papillomavirus E7 oncoproteins share functions with polyomavirus small T antigens. J Virol. 2015 Mar; 89(5):2857-65. View in: Pubmed

      • An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A. 2015 Jan 06; 112(1):232-7. View in: Pubmed

      • BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2015 Feb 18; 43(3):e19. View in: Pubmed

      • Erratum: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140044. View in: Pubmed

      • The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. Mol Cancer Res. 2015 Mar; 13(3):502-9. View in: Pubmed

      • Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest. 2014 Dec; 124(12):5411-23. View in: Pubmed

      • RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet. 2014 Dec; 46(12):1264-6. View in: Pubmed

      • Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140035. View in: Pubmed

      • The role of specific PP2A complexes in the dephosphorylation of ?H2AX. J Cell Sci. 2015 Jan 15; 128(2):421. View in: Pubmed

      • Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn. 2014 Nov; 16(6):660-72. View in: Pubmed

      • Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. J Virol. 2014 Oct; 88(20):12055-64. View in: Pubmed

      • Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol. 2014 Sep; 16(9):876-88. View in: Pubmed

      • KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014 Jul 03; 158(1):171-84. View in: Pubmed

      • Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples. PLoS One. 2014; 9(6):e99451. View in: Pubmed

      • PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene. 2015 Apr 16; 34(16):2061-71. View in: Pubmed

      • PP2A-mediated regulation of Ras signaling in G2 is essential for stable quiescence and normal G1 length. Mol Cell. 2014 Jun 19; 54(6):932-945. View in: Pubmed

      • A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014 Jul; 4(7):816-27. View in: Pubmed

      • Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014 Jul 03; 124(1):13-23. View in: Pubmed

      • Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014 Jun; 46(6):618-23. View in: Pubmed

      • Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84. View in: Pubmed

      • ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 2014 Mar; 20(3):251-4. View in: Pubmed

      • Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr Biol (Camb). 2014 Apr; 6(4):388-98. View in: Pubmed

      • Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1873-83. View in: Pubmed

      • Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014 Apr; 4(4):452-65. View in: Pubmed

      • ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep. 2014 Jan 30; 6(2):313-24. View in: Pubmed

      • Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol. 2014 Mar; 34(6):1136-44. View in: Pubmed

      • Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014 Feb; 46(2):161-5. View in: Pubmed

      • In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1102-7. View in: Pubmed

      • TRAF2 is an NF-?B-activating oncogene in epithelial cancers. Oncogene. 2015 Jan 08; 34(2):209-16. View in: Pubmed

      • Genomic insights into WNT/ß-catenin signaling. Trends Pharmacol Sci. 2014 Feb; 35(2):103-9. View in: Pubmed

      • An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer. Oncogene. 2014 Dec 04; 33(49):5637-48. View in: Pubmed

      • Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A. 2013 Nov 26; 110(48):19489-94. View in: Pubmed

      • The perfect storm: challenges and opportunities for translational medicine. J Clin Invest. 2013 Nov; 123(11):4963-6. View in: Pubmed

      • A Case of Persistent Helicobacter pylori Infection Occurring with Anti-IgE Immunosuppression. ACG Case Rep J. 2013 Oct; 1(1):16-8. View in: Pubmed

      • Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One. 2013; 8(9):e74950. View in: Pubmed

      • Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. Clin Cancer Res. 2013 Nov 01; 19(21):5960-71. View in: Pubmed

      • Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013 Nov 01; 119(21):3776-83. View in: Pubmed

      • Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov. 2013 Sep; 3(9):1044-57. View in: Pubmed

      • HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell. 2013 Jun 06; 153(6):1327-39. View in: Pubmed

      • The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature. 2013 Jun 13; 498(7453):246-50. View in: Pubmed

      • RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013 Jun; 123(6):2551-63. View in: Pubmed

      • Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93. View in: Pubmed

      • Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep. 2013 Mar 28; 3(3):747-58. View in: Pubmed

      • IKKe-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Rep. 2013 Mar 28; 3(3):724-33. View in: Pubmed

      • Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013 Mar; 45(3):285-9. View in: Pubmed

      • Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev. 2013 Jan 15; 27(2):197-210. View in: Pubmed

      • ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res. 2013 Apr; 23(4):665-78. View in: Pubmed

      • ß-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012 Dec 21; 151(7):1457-73. View in: Pubmed

      • Integrative functional genomics identifies RINT1 as a novel GBM oncogene. Neuro Oncol. 2012 Nov; 14(11):1325-31. View in: Pubmed

      • High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Invest Ophthalmol Vis Sci. 2012 Oct 09; 53(11):6991-6. View in: Pubmed

      • I?B kinase e phosphorylates TRAF2 to promote mammary epithelial cell transformation. Mol Cell Biol. 2012 Dec; 32(23):4756-68. View in: Pubmed

      • Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 04; 109(36):14476-81. View in: Pubmed

      • Cancer vulnerabilities unveiled by genomic loss. Cell. 2012 Aug 17; 150(4):842-54. View in: Pubmed

      • Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med. 2012 Aug 15; 4(147):147ra112. View in: Pubmed

      • Nek4 regulates entry into replicative senescence and the response to DNA damage in human fibroblasts. Mol Cell Biol. 2012 Oct; 32(19):3963-77. View in: Pubmed

      • Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet. 2012; 8(7):e1002772. View in: Pubmed

      • Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A. 2012 Jul 10; 109(28):11252-7. View in: Pubmed

      • Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood. 2012 Aug 02; 120(5):1095-106. View in: Pubmed

      • Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Invest. 2012 Jul; 122(7):2369-83. View in: Pubmed

      • MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Sci Signal. 2012 May 15; 5(224):rs4. View in: Pubmed

      • EGFR in limbo. Cell. 2012 May 11; 149(4):735-7. View in: Pubmed

      • Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012 Apr 15; 26(8):756-84. View in: Pubmed

      • The intersection of genetic and chemical genomic screens identifies GSK-3a as a target in human acute myeloid leukemia. J Clin Invest. 2012 Mar; 122(3):935-47. View in: Pubmed

      • PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene. 2012 Jul 19; 31(29):3397-408. View in: Pubmed

      • High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012 Jan; 2(1):82-93. View in: Pubmed

      • RMRP is a non-coding RNA essential for early murine development. PLoS One. 2011; 6(10):e26270. View in: Pubmed

      • Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011 Dec; 1(7):608-25. View in: Pubmed

      • High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One. 2011; 6(9):e24433. View in: Pubmed

      • Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 04; 43(10):964-968. View in: Pubmed

      • BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16; 146(6):904-17. View in: Pubmed

      • Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov. 2011 Sep; 1(4):297-311. View in: Pubmed

      • Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A. 2011 Jul 26; 108(30):12372-7. View in: Pubmed

      • Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A. 2011 Dec 20; 108(51):20388-93. View in: Pubmed

      • The JAK2/STAT3 signaling pathway is required for growth of CD44?CD24? stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011 Jul; 121(7):2723-35. View in: Pubmed

      • A public genome-scale lentiviral expression library of human ORFs. Nat Methods. 2011 Jun 26; 8(8):659-61. View in: Pubmed

      • Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine. Mol Cancer Ther. 2011 Sep; 10(9):1611-23. View in: Pubmed

      • Towards systematic functional characterization of cancer genomes. Nat Rev Genet. 2011 Jun 17; 12(7):487-98. View in: Pubmed

      • Identification of a novel urothelial carcinoma (UC) biomarker of lethality. J Clin Oncol. 2011 May 20; 29(15_suppl):4569. View in: Pubmed

      • Tumor genomic profiling of FFPE samples by massively parallel sequencing. J Clin Oncol. 2011 May 20; 29(15_suppl):10502. View in: Pubmed

      • Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72. View in: Pubmed

      • Making sense of cancer genomic data. Genes Dev. 2011 Mar 15; 25(6):534-55. View in: Pubmed

      • Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011 Aug 01; 29(22):3085-96. View in: Pubmed

      • Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol. 2011 Mar; 13(3):292-302. View in: Pubmed

      • Therapeutic implications of GIPC1 silencing in cancer. PLoS One. 2010 Dec 30; 5(12):e15581. View in: Pubmed

      • Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 2010 Dec 15; 70(24):10474-84. View in: Pubmed

      • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16; 468(7326):968-72. View in: Pubmed

      • Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation--rationale, methods and preliminary results from a Sino-American collaboration. Fitoterapia. 2011 Jan; 82(1):17-33. View in: Pubmed

      • Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204. View in: Pubmed

      • Emerging roles for the non-canonical IKKs in cancer. Oncogene. 2011 Feb 10; 30(6):631-41. View in: Pubmed

      • CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol. 2010 Dec; 24(12):2267-80. View in: Pubmed

      • Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest. 2010 Nov; 120(11):3940-52. View in: Pubmed

      • Towards patient-based cancer therapeutics. Nat Biotechnol. 2010 Sep; 28(9):904-6. View in: Pubmed

      • Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Ther. 2010 Dec; 17(12):1442-52. View in: Pubmed

      • PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One. 2010 Jul 23; 5(7):e11729. View in: Pubmed

      • CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. Int J Cancer. 2010 Jun 15; 126(12):2863-73. View in: Pubmed

      • On or off target: mutations, models, and predictions. Sci Transl Med. 2010 Jun 09; 2(35):35ps28. View in: Pubmed

      • Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A. 2010 Jun 22; 107(25):11501-6. View in: Pubmed

      • Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 Sep 16; 116(11):1919-23. View in: Pubmed

      • Functional genomics and cancer drug target discovery. Curr Opin Mol Ther. 2010 Jun; 12(3):284-93. View in: Pubmed

      • PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell. 2010 May 18; 17(5):497-509. View in: Pubmed

      • An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010 Mar 16; 17(3):298-310. View in: Pubmed

      • An oncogenic role for ETV1 in melanoma. Cancer Res. 2010 Mar 01; 70(5):2075-84. View in: Pubmed

      • An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med. 2010 Mar; 16(3):286-94. View in: Pubmed

      • CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS One. 2010 Feb 01; 5(2):e8979. View in: Pubmed

      • Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell. 2010 Mar 15; 21(6):1140-52. View in: Pubmed

      • Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009 Nov 18; 4(11):e7887. View in: Pubmed

      • Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009 Nov 06; 16(5):413-24. View in: Pubmed

      • Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009 Nov 05; 462(7269):108-12. View in: Pubmed

      • Regulating TERT: location, location, location. Cell Cycle. 2009 Oct 15; 8(20):3257. View in: Pubmed

      • Revving the Throttle on an oncogene: CDK8 takes the driver seat. Cancer Res. 2009 Oct 15; 69(20):7899-901. View in: Pubmed

      • Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009 Oct 06; 16(4):281-94. View in: Pubmed

      • SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009 Nov; 41(11):1238-42. View in: Pubmed

      • MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res. 2009 Oct 01; 69(19):7803-10. View in: Pubmed

      • An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature. 2009 Sep 10; 461(7261):230-5. View in: Pubmed

      • SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal. 2009 Jul 21; 2(80):ra35. View in: Pubmed

      • AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009 Jul 07; 16(1):21-32. View in: Pubmed

      • Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009 May 29; 137(5):821-34. View in: Pubmed

      • Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell. 2009 May 14; 34(4):461-72. View in: Pubmed

      • Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009 Apr 01; 101(7):519-32. View in: Pubmed

      • PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res. 2009 Apr 01; 69(7):2870-7. View in: Pubmed

      • Bladder cancer: modeling and translation. Genes Dev. 2009 Mar 15; 23(6):655-9. View in: Pubmed

      • Integrative genomic approaches to understanding cancer. Biochim Biophys Acta. 2009 Jun; 1790(6):478-84. View in: Pubmed

      • Genetic and cellular mechanisms of oncogenesis. Curr Opin Genet Dev. 2009 Feb; 19(1):1-3. View in: Pubmed

      • Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20380-5. View in: Pubmed

      • BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One. 2008; 3(12):e3949. View in: Pubmed

      • Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A. 2008 Dec 09; 105(49):19372-7. View in: Pubmed

      • Suppression of hPOT1 in diploid human cells results in an hTERT-dependent alteration of telomere length dynamics. Mol Cancer Res. 2008 Oct; 6(10):1582-93. View in: Pubmed

      • CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008 Sep 25; 455(7212):547-51. View in: Pubmed

      • A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 2008 Aug 12; 14(2):146-55. View in: Pubmed

      • Unexpected pieces to the senescence puzzle. Cell. 2008 Jun 13; 133(6):958-61. View in: Pubmed

      • SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev. 2008 Jun; 27(2):137-46. View in: Pubmed

      • The current state of preclinical prostate cancer animal models. Prostate. 2008 May 01; 68(6):629-39. View in: Pubmed

      • Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008 May; 13(5):394-406. View in: Pubmed

      • The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One. 2008 Apr 16; 3(4):e2020. View in: Pubmed

      • Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 2008 Apr; 13(4):355-64. View in: Pubmed

      • Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 2008 Apr; 14(4):152-60. View in: Pubmed

      • TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene. 2008 Jun 12; 27(26):3754-60. View in: Pubmed

      • Oncogenic transformation and experimental models of human cancer. Front Biosci. 2008 Jan 01; 13:71-84. View in: Pubmed

      • Liprin alpha1 interacts with PP2A B56gamma. Cell Cycle. 2008 Feb 15; 7(4):525-32. View in: Pubmed

      • Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007 Nov 01; 21(21):2683-710. View in: Pubmed

      • Structural basis of PP2A inhibition by small t antigen. PLoS Biol. 2007 Aug; 5(8):e202. View in: Pubmed

      • The role of PP2A A subunits in tumor suppression. Cell Adh Migr. 2007 Jul-Sep; 1(3):140-1. View in: Pubmed

      • Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15; 129(6):1065-79. View in: Pubmed

      • The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell. 2007 Jun 01; 129(5):969-82. View in: Pubmed

      • Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data. Bioinformatics. 2007 Jun 15; 23(12):1451-8. View in: Pubmed

      • Cancer genomics: integrating form and function. Carcinogenesis. 2007 Jul; 28(7):1387-92. View in: Pubmed

      • Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol. 2007; 39(9):1562-8. View in: Pubmed

      • Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis. Cell. 2006 Nov 17; 127(4):759-73. View in: Pubmed

      • Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods. 2006 Oct; 3(10):777-9. View in: Pubmed

      • Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006 Oct; 10(4):321-30. View in: Pubmed

      • Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods. 2006 Sep; 3(9):715-9. View in: Pubmed

      • Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006 Aug 17; 442(7104):818-22. View in: Pubmed

      • Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 2006 Jun 30; 125(7):1269-81. View in: Pubmed

      • Androgen-dependent regulation of Her-2/neu in prostate cancer cells. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10099. View in: Pubmed

      • Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 2006 Jun 01; 66(11):5723-8. View in: Pubmed

      • PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem. 2006 Aug 11; 281(32):23003-12. View in: Pubmed

      • A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006 Mar 24; 124(6):1283-98. View in: Pubmed

      • Roots and stems: stem cells in cancer. Nat Med. 2006 Mar; 12(3):296-300. View in: Pubmed

      • Computational causal reasoning models of mechanisms of androgen stimulation in prostate cancer. Conf Proc IEEE Eng Med Biol Soc. 2006; 2006:38. View in: Pubmed

      • Involvement of PP2A in viral and cellular transformation. Oncogene. 2005 Nov 21; 24(52):7746-55. View in: Pubmed

      • Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis. Proc Natl Acad Sci U S A. 2005 Oct 25; 102(43):15599-604. View in: Pubmed

      • Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov; 2(11):e313. View in: Pubmed

      • Cancer genetics: Finding the right mix. Eur J Hum Genet. 2005 Oct; 13(10):1099-100. View in: Pubmed

      • Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res. 2005 Sep 15; 65(18):8183-92. View in: Pubmed

      • The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell. 2005 Sep; 9(3):327-38. View in: Pubmed

      • Transformation of human and murine fibroblasts without viral oncoproteins. Mol Cell Biol. 2005 Aug; 25(15):6464-74. View in: Pubmed

      • Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy. Hum Gene Ther. 2005 Jul; 16(7):859-68. View in: Pubmed

      • Identification of the androgen-induced transcriptional program of human prostate cancer revealed by causal analysis. J Clin Oncol. 2005 Jun; 23(16_suppl):4637. View in: Pubmed

      • The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A. 2005 Jun 07; 102(23):8222-7. View in: Pubmed

      • Analysis of telomeric single-strand overhang length in human endometrial cancers. FEBS Lett. 2005 May 23; 579(13):2959-64. View in: Pubmed

      • Telomerase: regulation, function and transformation. Crit Rev Oncol Hematol. 2005 May; 54(2):85-93. View in: Pubmed

      • Genetic alterations in prostate cancer. Clin Prostate Cancer. 2005 Mar; 3(4):220-9. View in: Pubmed

      • Telomere and telomerase dynamics in human cells. Curr Mol Med. 2005 Mar; 5(2):227-31. View in: Pubmed

      • Understanding transformation: progress and gaps. Curr Opin Genet Dev. 2005 Feb; 15(1):13-7. View in: Pubmed

      • Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004 Dec 15; 64(24):8867-75. View in: Pubmed

      • Signaling and transcriptional changes critical for transformation of human cells by simian virus 40 small tumor antigen or protein phosphatase 2A B56gamma knockdown. Cancer Res. 2004 Oct 01; 64(19):6978-88. View in: Pubmed

      • Nucleolin interacts with telomerase. J Biol Chem. 2004 Dec 03; 279(49):51508-15. View in: Pubmed

      • Cancer: surviving on the edge. Cancer Cell. 2004 Sep; 6(3):215-22. View in: Pubmed

      • Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol. 2004 Aug; 24(16):7024-31. View in: Pubmed

      • Indications for BRCA1 and BRCA2 mutation testing in hereditary breast and ovarian cancer families. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9720. View in: Pubmed

      • Functional genetics and experimental models of human cancer. Trends Mol Med. 2004 Jul; 10(7):344-50. View in: Pubmed

      • Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol Cell Biol. 2004 Jun; 24(12):5459-74. View in: Pubmed

      • Immortalized cells as experimental models to study cancer. Cytotechnology. 2004 Jun; 45(1-2):47-59. View in: Pubmed

      • Experimental models of human cancer. Cell Cycle. 2004 May; 3(5):604-5. View in: Pubmed

      • Viral vector-mediated transduction of a modified thrombospondin-2 cDNA inhibits tumor growth and angiogenesis. Gene Ther. 2004 May; 11(9):739-45. View in: Pubmed

      • A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004 Apr; 6(4):308-18. View in: Pubmed

      • A genetically defined model for human ovarian cancer. Cancer Res. 2004 Mar 01; 64(5):1655-63. View in: Pubmed

      • Targeting cancer with telomerase: commentary re Q. Huang et al., a novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin. Cancer Res., 10: 1439-1445, 2004. Clin Cancer Res. 2004 Feb 15; 10(4):1203-5. View in: Pubmed

      • In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues. Oncol Rep. 2004 Feb; 11(2):297-302. View in: Pubmed

      • Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell. 2004 Feb; 5(2):127-36. View in: Pubmed

      • Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004 Feb 01; 10(3):828-39. View in: Pubmed

      • The origin of cancer. Cancer Treat Res. 2004; 122:1-22. View in: Pubmed

      • New Functions for Telomerase. Cancer Res Treat. 2003 Dec; 35(6):467-71. View in: Pubmed

      • Telomerase expression--only half the story. Cancer Biol Ther. 2003 Nov-Dec; 2(6):685-6. View in: Pubmed

      • Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene Ther. 2003 Sep; 10(18):1543-50. View in: Pubmed

      • Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein. Gene Ther. 2003 Aug; 10(15):1216-24. View in: Pubmed

      • Telomerase maintains telomere structure in normal human cells. Cell. 2003 Jul 25; 114(2):241-53. View in: Pubmed

      • Evolving views of telomerase and cancer. Trends Cell Biol. 2003 Jun; 13(6):289-94. View in: Pubmed

      • Telomerase and tumorigenesis. Cancer Lett. 2003 May 15; 194(2):163-72. View in: Pubmed

      • Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol. 2003 May 15; 21(10):2034-43. View in: Pubmed

      • Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell. 2003 May; 3(5):483-95. View in: Pubmed

      • SV40 early region oncoproteins and human cell transformation. Histol Histopathol. 2003 04; 18(2):541-50. View in: Pubmed

      • Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 2003 Apr; 9(4):493-501. View in: Pubmed

      • Chemosensitivity linked to p73 function. Cancer Cell. 2003 Apr; 3(4):403-10. View in: Pubmed

      • Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits Ras-induced anchorage-independent growth in telomerase-immortalized human fibroblasts. Mol Cell Biol. 2003 Apr; 23(8):2859-70. View in: Pubmed

      • Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet. 2003 Apr; 33(4):492-6. View in: Pubmed

      • Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003 Mar; 3(3):285-96. View in: Pubmed

      • Rules for making human tumor cells. N Engl J Med. 2002 Nov 14; 347(20):1593-603. View in: Pubmed

      • Empty pockets yield more telomere change. Cell Cycle. 2002 Nov-Dec; 1(6):406-7. View in: Pubmed

      • Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A. 2002 Oct 01; 99(20):12606-11. View in: Pubmed

      • Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 2002 Sep; 8(9):979-86. View in: Pubmed

      • Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene. 2002 Jul 04; 21(29):4577-86. View in: Pubmed

      • A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol. 2002 Jul; 22(14):5157-72. View in: Pubmed

      • Senescence, telomere shortening and telomere maintenance. Cancer Biol Ther. 2002 Jul-Aug; 1(4):398-400. View in: Pubmed

      • Immortalization and transformation of human cells. Mol Cells. 2002 Jun 30; 13(3):351-61. View in: Pubmed

      • Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002 May; 2(5):331-41. View in: Pubmed

      • Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol. 2002 Apr; 22(7):2111-23. View in: Pubmed

      • Prospects for anti-neoplastic therapies based on telomere biology. Curr Cancer Drug Targets. 2002 Mar; 2(1):1-17. View in: Pubmed

      • Derivation of human tumor cells in vitro without widespread genomic instability. Cancer Res. 2001 Dec 15; 61(24):8838-44. View in: Pubmed

      • Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res. 2001 Dec 01; 61(23):8366-70. View in: Pubmed

      • Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res. 2001 Nov; 7(11):3343-8. View in: Pubmed

      • Telomerase and cancer: where and when? Clin Cancer Res. 2001 Oct; 7(10):2953-4. View in: Pubmed

      • Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J Clin Invest. 2001 Sep; 108(5):725-32. View in: Pubmed

      • Telomerase activation, cellular immortalization and cancer. Ann Med. 2001 Mar; 33(2):123-9. View in: Pubmed

      • The Saccharomyces cerevisiae WRN homolog Sgs1p participates in telomere maintenance in cells lacking telomerase. EMBO J. 2001 Feb 15; 20(4):905-13. View in: Pubmed

      • Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 2001 Jan 01; 15(1):50-65. View in: Pubmed

      • Genes involved in senescence and immortalization. Curr Opin Cell Biol. 2000 Dec; 12(6):705-9. View in: Pubmed

      • Complications during root canal irrigation--literature review and case reports. Int Endod J. 2000 May; 33(3):186-93. View in: Pubmed

      • Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol. 2000 Feb; 20(4):1436-47. View in: Pubmed

      • Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999 Oct; 5(10):1164-70. View in: Pubmed

      • Creation of human tumour cells with defined genetic elements. Nature. 1999 Jul 29; 400(6743):464-8. View in: Pubmed

      • The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999 Jun; 10(6):673-9. View in: Pubmed

      • Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A. 1998 Dec 08; 95(25):14723-8. View in: Pubmed

      • Diagnosis in Oncology. Leukemia cutis. J Clin Oncol. 1997 May; 15(5):2170-1. View in: Pubmed

      • Intracellular mediators regulate CD2 lateral diffusion and cytoplasmic Ca2+ mobilization upon CD2-mediated T cell activation. Biophys J. 1995 Feb; 68(2):459-70. View in: Pubmed

      • Separable portions of the CD2 cytoplasmic domain involved in signaling and ligand avidity regulation. J Exp Med. 1993 Nov 01; 178(5):1831-6. View in: Pubmed

      • T cell adhesion, avidity regulation and signaling: a molecular analysis of CD2. Semin Immunol. 1993 Aug; 5(4):249-61. View in: Pubmed

      • The complete sequences of plasmids pFNeo and pMH-Neo: convenient expression vectors for high-level expression of eukaryotic genes in hematopoietic cell lines. Gene. 1993 May 30; 127(2):267-8. View in: Pubmed

      • Signal transduction pathways involved in T cell receptor-induced regulation of CD2 avidity for CD58. J Immunol. 1993 Apr 01; 150(7):2607-19. View in: Pubmed

      • CD4, CD8 and CD2 in T cell adhesion and signaling. Curr Top Microbiol Immunol. 1993; 184:223-33. View in: Pubmed

      • A distinct cytoplasmic domain of CD2 regulates ligand avidity and T-cell responsiveness to antigen. Proc Natl Acad Sci U S A. 1992 Aug 01; 89(15):7179-83. View in: Pubmed

      • Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59. Science. 1992 Jun 26; 256(5065):1805-7. View in: Pubmed

      • CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1. Nature. 1991 Nov 21; 354(6350):233-5. View in: Pubmed

      • Interaction of CD2 with its ligand lymphocyte function-associated antigen-3 induces adenosine 3',5'-cyclic monophosphate production in T lymphocytes. J Immunol. 1991 Jul 01; 147(1):14-21. View in: Pubmed

      • Cloned cDNA sequence for the human mesothelial protein 'mesosecrin' discloses its identity as a plasminogen activator inhibitor (PAI-1) and a recent evolutionary change in transcript processing. J Cell Sci. 1989 Sep; 94 ( Pt 1):1-10. View in: Pubmed

      • Mesosecrin: a secreted glycoprotein produced in abundance by human mesothelial, endothelial, and kidney epithelial cells in culture. J Cell Biol. 1987 Feb; 104(2):263-75. View in: Pubmed

      • Cloning and sequence of DNA encoding structural proteins of the autonomous parvovirus feline panleukopenia virus. J Virol. 1985 Sep; 55(3):574-82. View in: Pubmed

      • Clinical signs for the early recognition of cancer of the oral cavity. Int Dent J. 1977 Jun 02; 27(2):165-71. View in: Pubmed

      • [Blood sugar and plasma insulin levels in children following the oral administration of glybenclamide (HB 419)]. Z Kinderheilkd. 1970; 108(1):32-40. View in: Pubmed


      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Dana 1538 Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Dana 1538 Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      William C. Hahn, MD, PhD

      About Our Ratings

      Physician Star Rating Comment Block